生物标志物在恶性胸腔积液诊断中的研究进展

聪聪 赵(承德医学院附属医院，中国)
桂芬 庞(承德医学院附属医院，中国)

摘要

胸腔积液在临床上较为常见，可通过影像学诊断，然而病因诸多，如结核性、恶性、肺炎旁胸腔积液及心力衰竭或肝硬化所致胸腔积液等，明确诊断极有挑战性。恶性胸腔积液患者预后差，早诊断、早治疗可抑制肿瘤进展和改善预后。在临床实践中，生物标志物检测具有无创、方便、易于开展等优点，可用于诊断恶性胸腔积液。本文就具有潜在诊断价值的生物标志物在恶性胸腔积液诊断中的研究进展进行综述，以期为恶性胸腔积液临床诊治提供参考依据。

关键词

恶性胸腔积液；生物标志物；诊断

参考

GE S, ZHAO Y, LIANG J, et al. Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications [J]. Cancer cell international, 2024, 24(1): 105.

FERREIRO L, SUáREZ-ANTELO J, ÁLVAREZ-DOBAñO J M, et al. Malignant Pleural Effusion: Diagnosis and Management [J]. Canadian respiratory journal, 2020, 2020: 2950751.

ZHU J, FENG M, LIANG L, et al. Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis [J]. BMC cancer, 2017, 17(1): 590.

YANG Y, LIU Y L, SHI H Z. Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis [J]. Respiration; international review of thoracic diseases, 2017, 94(1): 62-9.

FENG M, ZHU J, LIANG L, et al. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis [J]. International journal of clinical oncology, 2017, 22(2): 283-90.

CHEN Y, MATHY N W, LU H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review) [J]. Molecular medicine reports, 2018, 17(6): 8019-30.

XIANG Z, DENG X, HE W, et al. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy [J]. Annals of medicine, 2022, 54(1): 1357-71.

CHANGCHIEN C Y, CHANG H H, DAI M S, et al. Distinct JNK/VEGFR signaling on angiogenesis of breast cancer-associated pleural fluid based on hormone receptor status [J]. Cancer science, 2021, 112(2): 781-91.

GAO L, WANG W, ZHANG Y, et al. Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion: a multicenter retrospective study [J]. Therapeutic advances in respiratory disease, 2023, 17: 17534666231155747.

VERMA A, ABISHEGANADEN J, LIGHT R W. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio) [J]. Lung, 2016, 194(1): 147-53.

曾婷婷, 胡雪茹, 王淑妍, 等. 基于腺苷脱氨酶相关检测指标诊断恶性胸腔积液的临床研究 [J]. 中国呼吸与危重监护杂志, 2024, 23(02): 105-9.

MAHLEY R W. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders [J]. Journal of molecular medicine (Berlin, Germany), 2016, 94(7): 739-46.

XUE Q, FANG G, DENG X, et al. The value of apolipoprotein E in distinguishing benign and malignant unilateral pleural effusions [J]. Medicine, 2020, 99(10): e19320.

TYAN Y C, WU H Y, LAI W W, et al. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry [J]. Journal of proteome research, 2005, 4(4): 1274-86.

刘晔, 王立峰. 恶性胸腔积液诊治的研究进展 [J]. 肿瘤防治研究, 2024, 51(10): 877-82.

CHEN L, ZHANG G, SHENG S, et al. Upregulation of soluble B7-H3 in NSCLC-derived malignant pleural effusion: A potential diagnostic biomarker correlated with NSCLC staging [J]. Clinica chimica acta; international journal of clinical chemistry, 2016, 457: 81-5.

JING X, WEI F, LI J, et al. Diagnostic value of soluble B7-H4 and carcinoembryonic antigen in distinguishing malignant from benign pleural effusion [J]. The clinical respiratory journal, 2018, 12(3): 986-90.

崔晓阳, 刘国栋, 郭慧娟, 等. 血清外泌体CEA、CA15-3和CA125水平在非小细胞肺癌和肺部良性病变鉴别诊断中的价值[J]. 检验医学, 2024, 39(11): 1035-41.

HUANG Y, WANG J, YAO Q, et al. Exosomes in malignant pleural effusions: Sources and applications [J]. Chinese medical journal, 2024, 137(11): 1381-3.

CREANEY J, DICK I M, LEON J S, et al. A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ [J]. Cancer genomics & proteomics, 2017, 14(2): 103-17.

TAMIYA H, MITANI A, SAITO A, et al. Exosomal MicroRNA Expression Profiling in Patients with Lung Adenocarcinoma-associated Malignant Pleural Effusion [J]. Anticancer research, 2018, 38(12): 6707-14.

WANG Y, XU Y M, ZOU Y Q, et al. Identification of differential expressed PE exosomal miRNA in lung adenocarcinoma, tuberculosis, and other benign lesions [J]. Medicine, 2017, 96(44): e8361.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v8i2.24001